Skip to main content

Effect of 3.2% vs 3.8% sodium citrate concentration on routine coagulation testing.

Adcock DM, Kressin DC, Marlar RA

Publication: Am J Clin Pathol (1997) • Vol 107 • Page 105-10PMID: 8980376View on PubMed

Purpose

The purpose of this paper was to determine the effects of sodium citrate concentration and assay reagent on prothrombin time (PT) and activated partial thromboplastin time (aPTT).

Conclusion

Citrate concentration (3.2% versus 3.8%) affects PT and aPTT results for all patients and healthy volunteers when the responsive reagents Innovin and Actin FS are used in the assays and for patients on IV heparin when the nonresponsive reagents Thromboplastin C+ and Actin are used.

Studies (1)

Purpose

The purpose of this study was to determine the effects of sodium citrate concentration and assay reagent on PT and aPTT in plasma from healthy volunteers and patients on anticoagulant therapy.

Summary of Findings

When the responsive reagents (Actin FS and Innovin) were used, the normal ranges of aPTT and PT increased when specimens from healthy volunteers were collected in 3.8% citrate compared to 3.2% citrate (both p<0.001). There was no significant difference in aPTT or PT ranges between specimens from healthy volunteers collected in 3.8 or 3.2% citrate when the nonresponsive reagents (Actin and Thromboplastin C+) were used in the assays. Specimens collected from all four treatment groups (no anticoagulant, IV heparin, oral anticoagulants, or both anticoagulant therapies) into 3.8% citrate had significantly higher PT values than those collected into 3.2% citrate with Innovin. When Thromboplastin C+ was used, only the IV heparin therapy treatment group had longer PT when collected in 3.8% rather than 3.2% citrate. Specimens collected from all four treatment groups into 3.8% citrate had significantly higher aPTT values than those collected into 3.2% citrate with Actin FS. When Actin was used, this was only true for patients on IV heparin therapy, with or without additional oral anticoagulants.

  • Biospecimens

    FluidPlasma
    FluidBlood
  • Preservation Types

    None (Fresh)
  • Diagnoses

    Normal
    Not specified
  • Platforms

    MorphologyHematology/ auto analyzer
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionOther drugs
    IV heparin
    IV heparin and oral anticoagulants
    No anticoagulants
    Oral anticoagulants
    Biospecimen AcquisitionAnticoagulant
    Multiple concentrations evaluated
    Sodium citrate
    Hematology/ auto analyzer SpecificReaction solution
    Actin
    Actin FS
    Innovin
    Thromboplastin C+